ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
This is an open-label, single-arm, Phase II investigator-initiated trial of antibody-drug conjugate combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory solid tumors with HER-2 positive
Carcinoma|Solid Tumor
DRUG: ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2
Objective Response Rate （ORR）, Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)., 24 months
Progression-free Survival (PFS), PFS was defined as the time from the first administration of study treatment to the first occurrence of disease progression as determined by investigator using RECIST v1.1 or death from any cause, whichever comes first., 24 months|Disease control rate (DCR), DCR was defined as the percentage of participants with a complete response (CR), partial response (PR), or stable disease (SD), 24 months|Overall survival (OS), OS was defined as the time from the first administration of study treatment to death from any cause., 24 months|Adverse event, rate of adverse events, 24 months
This is an open-label, single-arm, Phase II investigator-initiated trial of antibody-drug conjugate combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory solid tumors with HER-2 positive